1383801-33-9

Upstream product

• 1102229-83-3 2-[4-(trifluoromethyl)phenyl]pyrimidine-5-carbaldehyde 
• 931-50-0 cyclohexylmagnesium bromide 
• 455-18-5 4-CF₃C₆H₄CN 

Downstream Products

• 1383801-36-2 cyclohexyl{2-[4-(trifluoromethyl)phenyl]pyrimidin-5-yl}methanone 
• 1383801-39-5 (+/-)-1-cyclohexyl-1-{2-[4-(trifluoromethyl)phenyl]pyrimidin-5-yl}methanamine 
• 1383801-42-0 (+/-)-methyl 6-[(cyclohexyl{2-[4-(trifluoromethyl)phenyl]pyrimidin-5-yl}methyl)amino]nicotinate 
• 1383801-45-3 (+/-)-6-[(cyclohexyl{2-[4-(trifluoromethyl)phenyl]pyrimidin-5-yl}methyl)amino]nicotinic acid 

Relevant academic research and scientific papers

Glucagon Receptor Modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.